PD-L1 underexpression

News alerts, weekly reports and conference planners

Entrez ID:

29126

Related biomarkers:

‹

›

PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab/relatlimab Sensitive: A1 - Approval N Engl J Med - 3 weeks (New B) nivolumab / relatlimab Sensitive : A1 N Engl J Med - 3wk	nivolumab/relatlimab Sensitive: A1 - Approval N Engl J Med - 3 weeks nivolumab / relatlimab Sensitive : A1 N Engl J Med - 3 weeks - (New B)
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : C1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : C1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : C1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : C1
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : C1	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : C1
PD-L1 underexpression	Lung Adenocarcinoma	PD-L1 underexpression	Lung Adenocarcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : C1	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : C1
PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	nivolumab Resistant: B - Late Trials nivolumab Resistant : B	nivolumab Resistant: B - Late Trials nivolumab Resistant : B
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
PD-L1 underexpression	Gastric Adenocarcinoma	PD-L1 underexpression	Gastric Adenocarcinoma	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B
PD-L1 underexpression	Esophageal Adenocarcinoma	PD-L1 underexpression	Esophageal Adenocarcinoma	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B
PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer	nivolumab + ipilimumab Sensitive: C1 - Off-label nivolumab + ipilimumab Sensitive : C1	nivolumab + ipilimumab Sensitive: C1 - Off-label nivolumab + ipilimumab Sensitive : C1
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	camrelizumab Sensitive: C3 – Early Trials camrelizumab Sensitive : C3	camrelizumab Sensitive: C3 – Early Trials camrelizumab Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	ipilimumab + cemiplimab Sensitive: C3 – Early Trials ipilimumab + cemiplimab Sensitive : C3	ipilimumab + cemiplimab Sensitive: C3 – Early Trials ipilimumab + cemiplimab Sensitive : C3
PD-L1 underexpression	Urothelial Cancer	PD-L1 underexpression	Urothelial Cancer	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3
PD-L1 underexpression	Mantle Cell Lymphoma	PD-L1 underexpression	Mantle Cell Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
PD-L1 underexpression	Cutaneous T-cell Lymphoma	PD-L1 underexpression	Cutaneous T-cell Lymphoma	durvalumab + lenalidomide Sensitive: C3 – Early Trials durvalumab + lenalidomide Sensitive : C3	durvalumab + lenalidomide Sensitive: C3 – Early Trials durvalumab + lenalidomide Sensitive : C3
PD-L1 underexpression	Triple Negative Breast Cancer	PD-L1 underexpression	Triple Negative Breast Cancer	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression	Acute Myelogenous Leukemia	PD-L1 underexpression	Acute Myelogenous Leukemia	XmAb14045 Sensitive: C3 – Early Trials XmAb14045 Sensitive : C3	XmAb14045 Sensitive: C3 – Early Trials XmAb14045 Sensitive : C3
PD-L1 underexpression	Malignant Pleural Mesothelioma	PD-L1 underexpression	Malignant Pleural Mesothelioma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab sarotalocan Sensitive: C3 – Early Trials cetuximab sarotalocan Sensitive : C3	cetuximab sarotalocan Sensitive: C3 – Early Trials cetuximab sarotalocan Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3
PD-L1 underexpression	Gastric Adenocarcinoma	PD-L1 underexpression	Gastric Adenocarcinoma	toripalimab + surufatinib Sensitive: C3 – Early Trials toripalimab + surufatinib Sensitive : C3	toripalimab + surufatinib Sensitive: C3 – Early Trials toripalimab + surufatinib Sensitive : C3
PD-L1 underexpression	Esophageal Squamous Cell Carcinoma	PD-L1 underexpression	Esophageal Squamous Cell Carcinoma	toripalimab + surufatinib Sensitive: C3 – Early Trials toripalimab + surufatinib Sensitive : C3	toripalimab + surufatinib Sensitive: C3 – Early Trials toripalimab + surufatinib Sensitive : C3
PD-L1 underexpression	Colorectal Cancer	PD-L1 underexpression	Colorectal Cancer	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3	atezolizumab + RG6180 Sensitive: C3 – Early Trials atezolizumab + RG6180 Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3
PD-L1 underexpression	Renal Cell Carcinoma	PD-L1 underexpression	Renal Cell Carcinoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
PD-L1 underexpression	Hepatocellular Cancer	PD-L1 underexpression	Hepatocellular Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer	PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	gemcitabine Sensitive: C3 – Early Trials gemcitabine Sensitive : C3	gemcitabine Sensitive: C3 – Early Trials gemcitabine Sensitive : C3

PD-L1 underexpression

Associations